Objectives: The potential of four polyether ionophores (lasalocid, monensin, narasin, salinomycin) as agents against antimicrobial resistant Gram-positive veterinary pathogens was investigated. This included an assessment of their in vitro efficacy and pharmacodynamic profiles and potential cytotoxic effects against a variety of mammalian cell lines.
Methods: Antimicrobial susceptibility testing against 301 isolates of Gram-positive veterinary pathogens was performed using the broth microdilution method according to CLSI guidelines. Spot-plating of microdilution plates and time-kill kinetics assays were performed to assess pharmacodynamic profiles. Erythrocyte haemolysis and WST-1 cell proliferation assays were used to assess cell cytotoxicity for mammalian cells. Formulations of lasalocid were prepared to assess in vivo efficacy using a murine model of staphylococcal skin and soft tissue infection and a Streptococcus uberis challenge model of bovine mastitis.
Results: Salinomycin, lasalocid and narasin exhibited bacteriostatic activity against all pathogens tested at ≤8 mg/L, including methicillin-resistant staphylococci. Monensin also exhibited bacteriostatic activity, but MIC values were elevated against phenotypically methicillin-resistant coagulase negative staphylococci. Time-kill kinetics assays also indicated that activity in vitro was retained over 24 hours. Narasin and monensin displayed the least mammalian cell toxicity. In vivo trials of bovine mastitis, demonstrated a 66.7% microbiological cure rate for cows treated with an intramammary preparation of lasalocid over a 3 day period, compared with the positive control with a microbial cure rate of 62.5%. Topical application of a pilot formulation of lasalocid in a staphylococcal skin and soft tissue infection model resulted in a 3log10 reduction in bacterial viable counts (CFU/g) over 7 days.
Conclusions: Polyether ionophores offer potentially novel treatments for veterinary applications. They have demonstrated safety against a variety of mammalian cells and efficacy in vivo against Gram-positive pathogens as well as efficacy in vitro against antimicrobial resistant isolates.